37226207|t|Arterial hypertension and beta-amyloid accumulation have spatially overlapping effects on posterior white matter hyperintensity volume: a cross-sectional study.
37226207|a|BACKGROUND: White matter hyperintensities (WMH) in subjects across the Alzheimer's disease (AD) spectrum with minimal vascular pathology suggests that amyloid pathology-not just arterial hypertension-impacts WMH, which in turn adversely influences cognition. Here we seek to determine the effect of both hypertension and Abeta positivity on WMH, and their impact on cognition. METHODS: We analysed data from subjects with a low vascular profile and normal cognition (NC), subjective cognitive decline (SCD), and amnestic mild cognitive impairment (MCI) enrolled in the ongoing observational multicentre DZNE Longitudinal Cognitive Impairment and Dementia Study (n = 375, median age 70.0 [IQR 66.0, 74.4] years; 178 female; NC/SCD/MCI 127/162/86). All subjects underwent a rich neuropsychological assessment. We focused on baseline memory and executive function-derived from multiple neuropsychological tests using confirmatory factor analysis-, baseline preclinical Alzheimer's cognitive composite 5 (PACC5) scores, and changes in PACC5 scores over the course of three years (DeltaPACC5). RESULTS: Subjects with hypertension or Abeta positivity presented the largest WMH volumes (pFDR < 0.05), with spatial overlap in the frontal (hypertension: 0.42 +- 0.17; Abeta: 0.46 +- 0.18), occipital (hypertension: 0.50 +- 0.16; Abeta: 0.50 +- 0.16), parietal lobes (hypertension: 0.57 +- 0.18; Abeta: 0.56 +- 0.20), corona radiata (hypertension: 0.45 +- 0.17; Abeta: 0.40 +- 0.13), optic radiation (hypertension: 0.39 +- 0.18; Abeta: 0.74 +- 0.19), and splenium of the corpus callosum (hypertension: 0.36 +- 0.12; Abeta: 0.28 +- 0.12). Elevated global and regional WMH volumes coincided with worse cognitive performance at baseline and over 3 years (pFDR < 0.05). Abeta positivity was negatively associated with cognitive performance (direct effect-memory: - 0.33 +- 0.08, pFDR < 0.001; executive: - 0.21 +- 0.08, pFDR < 0.001; PACC5: - 0.29 +- 0.09, pFDR = 0.006; DeltaPACC5: - 0.34 +- 0.04, pFDR < 0.05). Splenial WMH mediated the relationship between hypertension and cognitive performance (indirect-only effect-memory: - 0.05 +- 0.02, pFDR = 0.029; executive: - 0.04 +- 0.02, pFDR = 0.067; PACC5: - 0.05 +- 0.02, pFDR = 0.030; DeltaPACC5: - 0.09 +- 0.03, pFDR = 0.043) and WMH in the optic radiation partially mediated that between Abeta positivity and memory (indirect effect-memory: - 0.05 +- 0.02, pFDR = 0.029). CONCLUSIONS: Posterior white matter is susceptible to hypertension and Abeta accumulation. Posterior WMH mediate the association between these pathologies and cognitive dysfunction, making them a promising target to tackle the downstream damage related to the potentially interacting and potentiating effects of the two pathologies. TRIAL REGISTRATION: German Clinical Trials Register (DRKS00007966, 04/05/2015).
37226207	9	21	hypertension	Disease	MESH:D006973
37226207	106	127	matter hyperintensity	Disease	MESH:D056784
37226207	173	202	White matter hyperintensities	Disease	MESH:D056784
37226207	204	207	WMH	Disease	MESH:D056784
37226207	232	251	Alzheimer's disease	Disease	MESH:D000544
37226207	253	255	AD	Disease	MESH:D000544
37226207	312	319	amyloid	Disease	MESH:C000718787
37226207	348	360	hypertension	Disease	MESH:D006973
37226207	369	372	WMH	Disease	MESH:D056784
37226207	465	477	hypertension	Disease	MESH:D006973
37226207	482	487	Abeta	Gene	351
37226207	502	505	WMH	Disease	MESH:D056784
37226207	644	661	cognitive decline	Disease	MESH:D003072
37226207	663	666	SCD	Disease	MESH:D003072
37226207	682	707	mild cognitive impairment	Disease	MESH:D060825
37226207	709	712	MCI	Disease	MESH:D060825
37226207	782	802	Cognitive Impairment	Disease	MESH:D003072
37226207	807	815	Dementia	Disease	MESH:D003704
37226207	887	890	SCD	Disease	MESH:D003072
37226207	891	894	MCI	Disease	MESH:D060825
37226207	1127	1138	Alzheimer's	Disease	MESH:D000544
37226207	1273	1285	hypertension	Disease	MESH:D006973
37226207	1289	1294	Abeta	Gene	351
37226207	1328	1331	WMH	Disease	MESH:D056784
37226207	1392	1404	hypertension	Disease	MESH:D006973
37226207	1420	1425	Abeta	Gene	351
37226207	1453	1465	hypertension	Disease	MESH:D006973
37226207	1481	1486	Abeta	Gene	351
37226207	1519	1531	hypertension	Disease	MESH:D006973
37226207	1547	1552	Abeta	Gene	351
37226207	1585	1597	hypertension	Disease	MESH:D006973
37226207	1613	1618	Abeta	Gene	351
37226207	1652	1664	hypertension	Disease	MESH:D006973
37226207	1680	1685	Abeta	Gene	351
37226207	1739	1751	hypertension	Disease	MESH:D006973
37226207	1767	1772	Abeta	Gene	351
37226207	1818	1821	WMH	Disease	MESH:D056784
37226207	1917	1922	Abeta	Gene	351
37226207	2169	2172	WMH	Disease	MESH:D056784
37226207	2207	2219	hypertension	Disease	MESH:D006973
37226207	2430	2433	WMH	Disease	MESH:D056784
37226207	2489	2494	Abeta	Gene	351
37226207	2627	2639	hypertension	Disease	MESH:D006973
37226207	2644	2649	Abeta	Gene	351
37226207	2674	2677	WMH	Disease	MESH:D056784
37226207	2732	2753	cognitive dysfunction	Disease	MESH:D003072
37226207	Association	MESH:D000544	351
37226207	Association	MESH:D060825	351
37226207	Association	MESH:D003072	351
37226207	Association	MESH:D006973	351
37226207	Positive_Correlation	MESH:D056784	351

